IRVING, Texas, Aug. 15, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, has published a study in Oncotarget validating the analytical and clinical performance of MI Cancer Seek®. This FDA-approved assay is used as a companion diagnostic (CDx) to identify cancer patients who may benefit from targeted therapies. It includes one pan-cancer and five tumor-specific indications for numerous FDA-approved therapi ...

Caris Life Sciences (CAI) Q2 2025 Earnings Call August 12, 2025 04:30 PM ET Company ParticipantsNarendra Chokshi - SVP - Corporate DevelopmentBrian Brille - EVP & Vice ChairmanDavid Spetzler - PresidentLuke Power - SVP, CFO & Chief Accounting OfficerMichael Ryskin - Managing DirectorNone - ExecutiveVijay Kumar - Senior MDColleen Babington - Equity Research AssociatePatrick Donnelly - Managing DirectorConference Call ParticipantsDaniel Brennan - MD & Senior Equity Research AnalystRachel Vatnsdal - Senior Equ ...

Caris Life Sciences (CAI) Q2 2025 Earnings Call August 12, 2025 04:30 PM ET Speaker0Good afternoon, everyone, and welcome to the Keras Life Sciences Q2 twenty twenty five Earnings Call. My name is Kevin, and I'll be your coordinator today. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. Please be advised that this conference is being recorded.I would now like to hand it over to Narendra Chokshi with, Carus. Please go ah ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________________________ FORM 10-Q _________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to ____ Commission file number: 001-42706 __________ ...

Q2 2025 Earnings Call August 12, 2025 Where Molecular Science Meets Artificial Intelligence Important Information and Disclaimer Forward-Looking Statements This presentation contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding our business, solutions, plans, objecti ...

Caris Life Sciences Reports Second Quarter 2025 Financial Results Exhibit 99.1 IRVING, Texas, August 12, 2025— Caris Life Sciences, Inc. (Nasdaq: CAI), a leading, patient centric, next-generation AI TechBio company, today reported financial results for the quarter ended June 30, 2025. Second Quarter 2025 Financial Highlights "Our second quarter results show the strength of our comprehensive approach and we look forward to continuing to build on this momentum into the second half of 2025," said David D. Halb ...

Company Overview - Caris Life Sciences is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer [2] - The company is headquartered in Irving, Texas, with additional offices in Phoenix, New York, Cambridge (MA), Tokyo, Japan, and Basel, Switzerland [3] - Caris provides services in the U.S. and other international markets through its own operations and distributor partners [3] Financial Reporting - Caris Life Sciences will report its second quarter 2025 financial results on August 12, 2025 [1] - A conference call and live webcast will be held at 3:30 p.m. CT (4:30 p.m. ET) to discuss these financial results [1] - A replay of the webcast will be available shortly after the call on the Investor Relations section of the Caris Life Sciences website [1] Technological Capabilities - The company utilizes comprehensive molecular profiling, including Whole Exome and Whole Transcriptome Sequencing, combined with advanced AI and machine learning algorithms [2] - Caris has developed a large-scale, multimodal clinico-genomic database and computing capability to analyze the molecular complexity of diseases [2] - This integration of next-generation sequencing, AI, machine learning technologies, and high-performance computing enables the development of advanced precision medicine diagnostic solutions [2]